Compare RDCM & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RDCM | RCEL |
|---|---|---|
| Founded | 1985 | N/A |
| Country | Israel | United States |
| Employees | N/A | 226 |
| Industry | Computer peripheral equipment | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 205.1M | 171.5M |
| IPO Year | 1999 | N/A |
| Metric | RDCM | RCEL |
|---|---|---|
| Price | $16.07 | $4.40 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $18.00 | $7.88 |
| AVG Volume (30 Days) | 177.4K | ★ 211.8K |
| Earning Date | 05-13-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $11.50 | $17.17 |
| Revenue Next Year | $9.74 | $49.82 |
| P/E Ratio | $16.35 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.41 | $3.22 |
| 52 Week High | $16.49 | $9.85 |
| Indicator | RDCM | RCEL |
|---|---|---|
| Relative Strength Index (RSI) | 77.55 | 49.09 |
| Support Level | $12.26 | $4.37 |
| Resistance Level | $16.49 | $4.57 |
| Average True Range (ATR) | 0.74 | 0.37 |
| MACD | 0.27 | -0.06 |
| Stochastic Oscillator | 91.33 | 19.25 |
Radcom Ltd Ltd is engaged in providing network intelligence, 5G ready cloud-native, network intelligence solutions for telecom operators transitioning to 5G. The company has a network intelligence solution for 5G namely Radcom ACE. Its products consist of Radcom Network Visibility, Radcom Service Assurance, and Radcom Network Insights. It has offices in Israel, the United States, Brazil, and India. Key revenue is derived from sales in North America.
Avita is largely a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently used in most of the 140 US burn centers. Despite having product approval in Australia, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region, although international sales, particularly in Japan, are growing. Avita is domiciled, and has its primary listing, in the US.